Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 13, 2022
Reporting Period: Single event date (April 13, 2022)
Business Context: The filing serves as a Regulation FD disclosure to update the Company's corporate presentation intended for use at conferences and investor meetings.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
No material changes to financial performance or operations are reported in this document. The sole material event is the update and distribution of the Company's corporate presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company updated its corporate presentation (Exhibit 99.1) for investor relations purposes.
Legal Disclaimer: The information contained in Item 7.01 and the attached Corporate Presentation is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that Section. It is not incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review the attached Corporate Presentation (Exhibit 99.1) for updated strategic outlook and operational details.
- Verify that the presentation content is not legally binding or incorporated by reference into other SEC filings.
- Check subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains none.